Current filters:

Start a new search
Add filters:

Use filters to refine the search results.

Results 1-10 of 14 (Search time: 0.004 seconds).
Item hits:
PreviewIssue DateTitleAuthor(s)
2017Irinotecan-induced mucositis: the interactions and potential role of GLP-2 analoguesMayo, B.; Stringer, A.; Bowen, J.; Bateman, E.; Keefe, D.
2013Investigation of effect of nutritional drink on chemotherapy-induced mucosal injury and tumor growth in an established animal modelBateman, E.; Bowen, J.; Stringer, A.; Mayo, B.; Plews, E.; Wignall, A.; Greenberg, N.; Schiffrin, E.; Keefe, D.
2012Tumor control versus adverse events with targeted anticancer therapiesKeefe, D.; Bateman, E.
2017Irinotecan-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analysesCampbell, J.; Stephenson, M.; Bateman, E.; Peters, M.; Keefe, D.; Bowen, J.
2011The effect of ErbB inhibition on chemotherapy-induced intestinal damageMayo, B.; Bowen, J.; Stringer, A.; Bateman, E.; Plews, E.; Darby, J.; Boyle, F.; Keefe, D.; International MASCC/ISOO Symposium (2011 : Athens, Greece)
2010Gastrointestinal toxicity of targeted anti-cancer therapyKeefe, D.; Bateman, E.
2011Patient-reported outcomes in supportive careBateman, E.; Keefe, D.
2016Enabling oral SN38-based chemotherapy with a combined lipophilic prodrug and self-microemulsifying drug delivery systemBala, V.; Rao, S.; Bateman, E.; Keefe, D.; Wang, S.; Prestidge, C.
2015Management of mucositis during chemotherapy: from pathophysiology to pragmatic therapeuticsVan Sebille, Y.; Stansborough, R.; Wardill, H.; Bateman, E.; Gibson, R.; Keefe, D.
2014Apoptosis, proliferation and inflammation are improved after treatment with the new selective glp-2 receptor agonist, elsiglutide, in a rat model of irinotecan-induced mucositisMayo, B.; Stringer, A.; Bateman, E.; Bowen, J.; Wignall, A.; Wozniak, B.; White, I.; Pietra, C.; Cantoreggi, S.; Keefe, D.; COSA's 41st Annual Scientific Meeting. Joining Forces - Accelerating Progress (02 Dec 2014 - 04 Dec 2014 : Melbourne, Vic.)